ImmunityBio Inc (IBRX)

[123414]

This recent article from UroToday (01 April) reveals that the 2 year CR rate for N-803 is around 36%:

"In Cohort A, complete response was noted in 59 of 83 (71%) at the primary endpoint designated 3- or 6-month time point. Impressively, more than half (52%) had durable response out to 2 years or beyond."

52% of 59 = 30 out of 83 patients = 36%

This jives with Immunity Bio's announcement of their results in February:

"Indeed, the benchmark of 30% durable response at 18 to 24 months for a clinically meaningful therapy “is likely too high and may not be realistically achievable,”3 according to recommendations published in the Journal of Clinical Oncology. This “realistically unachievable” endpoint of 30% durable response at 18 months has in fact now been achieved and exceeded with the combination of Anktiva and BCG in this trial reported today. "

According to the list at the bottom of the following article TLD1433 is one of 14 trials currently going on in this space.